Aortic Stenosis Market will grow at highest pace owing to rising prevalence of aortic valve disorders

The Aortic Stenosis market comprises of transcatheter aortic valve replacement and surgical aortic valve replacement procedures. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that replaces a narrowed aortic valve without removing the old, diseased valve. It is performed through small incision in the groin, chest, or between the ribs. Surgical aortic valve replacement involves replacing the heart’s aortic valve during open-heart surgery. It is generally recommended for patients at low or intermediate risk of complications from the standard open-heart surgery.

The Global Aortic Stenosis Market is estimated to be valued at US$ 8.33 Bn in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030.

Key Takeaways
Key players operating in the Aortic Stenosis market are Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, CryoLife, Inc., Braile Biomédica, JenaValve Technology, Inc., Meril Life Sciences Pvt. Ltd., Micro Interventional Devices, Inc., and egnite, Inc. Edwards Lifesciences Corporation is one of the market leaders in the transcatheter aortic valve replacement devices.

The demand for aortic stenosis treatment procedures is increasing globally due to rising incidence of aortic valve disorders in aging population, availability of advanced transcatheter aortic valve replacement devices, and their advantages over open-heart surgeries. It is estimated that over 4 million people in the United States have aortic stenosis and approximately 200,000 new cases of aortic stenosis are diagnosed each year.

Technological advancements in the development of next generation transcatheter heart valves with better deliverability, placement properties, and longer durability are further supporting growth of this market. Introduction of lower profile delivery systems, steerable guide catheters, and transapical access devices have enabled treating patients with harder-to-reach anatomies.

Market Trends
Transcatheter mitral and tricuspid valve replacement – Major players are developing transcatheter mitral and tricuspid valve technologies to expand clinical applications of minimally-invasive cardiology and treat more types of valve diseases. Edwards Lifesciences is trialing its SAPIEN 3 transcatheter heart valve for transcatheter mitral valve replacement.

Preference for transcatheter procedures over open-heart surgeries – Younger patient populations are now being considered for transcatheter valve replacement due to favorable safety and outcomes of next-generation transcatheter valves. This trend is expected to accelerate market growth during forecast period.

Market Opportunities
Underpenetrated developing markets- Many developing countries have significantly larger aging populations and increasing burden of aortic stenosis and rheumatic heart diseases. However, markets in countries like India, China, Brazil remain underpenetrated representing major growth opportunities.

New transcatheter technologies in pipeline – Companies are developing newer transcatheter heart valve platforms and delivery systems which can overcome limitations of current generation devices such as requirement for balloon expandable valves. This includes self-expanding transcatheter heart valves.

Impact of COVID-19 on Aortic Stenosis Market
The COVID-19 pandemic has significantly impacted the growth of the aortic stenosis market. During the initial phases of the pandemic, the focus of healthcare providers shifted towards treating COVID-19 patients which resulted in postponing many non-essential procedures and appointments. This led to a decline in the number of procedures carried out for aortic stenosis in 2020. However, as the pandemic progressed, many providers started offering virtual consultations and remote monitoring services to manage patients with aortic stenosis. This helped in partially overcoming the challenges posed by social distancing norms.

Despite the initial setbacks, the demand for minimally invasive transcatheter aortic valve replacement (TAVR) procedures picked up momentum in the post-COVID scenario. The preference for TAVR rose sharply as it offered several benefits over open-heart surgeries such as quick recovery time, reduced hospital stay and lower risk of infection. Many hospitals also upgraded their facilities to conduct hybrid procedures. The development of enhanced delivery systems further augmented the uptake of TAVR. Moreover, growing awareness about timely diagnosis and treatment of aortic stenosis is anticipated to drive the market in the coming years. However, ongoing supply chain disruptions and price pressures remain obstacles.

Geographical Regions with Highest Value Concentration in Aortic Stenosis Market
Currently, the United States accounts for the largest share of the global aortic stenosis market in terms of value. This can be attributed to the rising geriatric population, availability of advanced treatment options and favorable reimbursement policies in the country. Europe holds the second position due to increasing adoption of TAVR and growing public funding for heart valve diseases. The market in countries like Germany, United Kingdom, France and Italy is well developed.

Fastest Growing Region in Aortic Stenosis Market
Asia Pacific is projected to witness the highest growth during the forecast period attributed to the rapidly aging population, economic development, increasing healthcare expenditure and growing medical tourism. Furthermore, the presence of untapped opportunities and rising awareness about valve diseases management are fueling the market expansion in the region. Countries like China, India, Japan and South Korea are expected to drive the APAC aortic stenosis market owing to their huge patient population and improving healthcare infrastructure.